Intranasal Foralumab (TZLS-401)
Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)
Phase 2Active - Phase 2a began 4Q 2023 (Expanded Access)
Key Facts
Indication
Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)
Phase
Phase 2
Status
Active - Phase 2a began 4Q 2023 (Expanded Access)
Company
About Tiziana Life Sciences
Tiziana Life Sciences is focused on developing breakthrough immunotherapies, primarily through intranasal delivery, to treat debilitating neurodegenerative conditions. Its core technology centers on foralumab, the only fully human anti-CD3 monoclonal antibody, which is in multiple Phase 2 trials for na-SPMS, Multiple System Atrophy, Alzheimer's, and ALS, with promising biomarker data recently reported. The company's strategy leverages a patent-protected platform until 2040 and is supported by grants and direct financings, positioning it to address significant unmet medical needs in neurology.
View full company profile